New COVID-19 Vaccine Data;  Protection Gained by 3rd and 4th Doses

Translate to Spanish or other 102 languages!

A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant. Image for illustration purposes
A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant. Image for illustration purposes

Mega Doctor News

- Advertisement -

A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant.

To evaluate effectiveness of 2, 3, and 4 doses of mRNA COVID-19 vaccines (Pfizer-BioNTech or Moderna) among adults with healthy immune systems, experts examined VISION Network data on more than 214,000 emergency department/urgent care visits and more than 58,000 hospitalizations with a COVID-19–like illness diagnosis in 10 U.S. states from mid-December 2021 through mid-June 2022. Study findings show:

  • When BA.1 was the predominant variant, vaccine effectiveness (VE) was 61% for two doses against COVID-19-associated hospitalizations; VE increased to between 85%–92% after receipt of a third/booster dose.
  • When BA.2/BA.2.12.1 became predominant, vaccine effectiveness with two doses was 24% against COVID-19-associated hospitalizations and increased to 52%–69% after a third/booster dose.
  • Patterns were similar for emergency department and urgent care encounters, with lower VE during BA.2/BA.2.12.1 predominance and higher VE with 3 or 4 doses compared to VE with 2 doses.
  • Among adults ages 50 years and older during BA.2/BA.2.12.1, vaccine effectiveness against COVID-19–associated hospitalization was 55% more than 4 months after a booster/third dose and increased to 80% more than a week after the fourth dose

COVID-19 vaccines remain our single most important tool to protect people against serious illness, hospitalization, and death. Getting vaccinated now will not prevent you from getting an authorized variant-specific vaccine in the fall or winter when they are recommended for you.  Given recent increases in deaths and hospitalizations associated with the BA.5 variant, everyone should stay up to date with recommended COVID-19 vaccinations, including additional booster doses for those who are moderately to severely immunocompromised and adults over 50.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Transplant Institute Bringing New Era to South Texas

Something significant is happening in medicine in the Rio Grande Valley. A level of specialized care that once routinely required Valley patients to travel hundreds of miles is now being delivered close to home — and earning recognition among leading kidney transplant programs in Texas and across the nation. DHR Health Transplant Institute has reached No. 2 in Texas and No. 16 nationally, marking an important moment for advanced medicine in South Texas.

DHR Health Transplant Success Signals a New Era for Advanced Medicine in the Rio Grande Valley

The significance of DHR Health Transplant Institute’s latest recognition extends far beyond a hospital ranking. It raises a larger question for South Texas: Has the Rio Grande Valley reached the point where patients can look to the region not only for local healthcare, but for nationally competitive transplant medicine?

STHS Earns Another 5-Star Healthgrades Distinction for Hip Fracture Care

For the sixth consecutive year, STHS McAllen and STHS Edinburg have earned a Five-Star Rating for Hip Fracture Treatment from Healthgrades, one of the nation's leading resources for evaluating hospital performance.

Raising Awareness, One Step at a Time: STHS Edinburg Hosts Sept. 23 Walkathon

To raise awareness about the condition and encourage residents to take proactive steps toward better vascular health, the STHS Limb Salvage & Amputation Prevention Program will host the Step Out PAD Walkathon on Wednesday, September 23, 2026, at STHS Edinburg, from 6:30 to 7:30 p.m.
- Advertisement -